US FDA gives CordenPharma Latina's Italian plant the all clear

By Gareth Macdonald

- Last updated on GMT

Google Maps
Google Maps

Related tags Pharmacology Pharmaceutical drug

CordenPharma Latina has resolved the problems that earned its API and injectable drug facility in Sermoneta, Italy a warning letter from the US FDA last year.

The US regulator gave the plant a clean bill of health in a closeout letter​ this month, explaining that: “Based on our evaluation, it appears that you have addressed the violations and or deviations.”

The Sermoneta facility – which was previously owned by Bristol Myers - makes oral and sterile liquid dosage forms antibiotics, including cephalosporin and penicillins. It was also cleared to manufacture freeze-dried cancer drugs for clinical trials in July 2015.

CordenPharma – which is owned by Germany-based International Chemical Investors Group (ICIG) – said addressing the issues – which were detailed in a warning letter in May​ last year – had involved a “holistic and systematic approach​.”

The firm declined to comment further when contacted by

Related news

Show more

Related products

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more